Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2026)

Arcus Biosciences' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $209.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 8.85% year-over-year to $209.0 million; the TTM figure through Mar 2026 stood at $209.0 million (up 8.85% YoY), while the FY2025 annual figure was $231.0 million, up 2.21% from the prior year.
• Total Current Liabilities was $209.0 million for Q1 2026 at Arcus Biosciences, down from $231.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $235.0 million in Q3 2025 to a low of $161.3 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $197.6 million across 5 years, with a median of $199.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities rose 25.81% in 2022, then dropped 5.88% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $193.0 million in 2022, then fell by 4.66% to $184.0 million in 2023, then increased by 22.83% to $226.0 million in 2024, then gained by 2.21% to $231.0 million in 2025, then retreated by 9.52% to $209.0 million in 2026.
• The last three Total Current Liabilities figures came in at $209.0 million (Q1 2026), $231.0 million (Q4 2025), and $235.0 million (Q3 2025), per Business Quant data.